Aurora Cannabis Inc. (ACB)
USD 4.84
(1.89%)
USD 4.84
(1.89%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 838.67 Million CAD | -9.46% |
| 2022 | 926.32 Million CAD | -14.57% |
| 2021 | 1.08 Billion CAD | -58.37% |
| 2020 | 2.6 Billion CAD | -6.43% |
| 2019 | 2.78 Billion CAD | -49.41% |
| 2018 | 5.5 Billion CAD | 188.0% |
| 2017 | 1.91 Billion CAD | 492.14% |
| 2016 | 322.67 Million CAD | 1654.02% |
| 2015 | 18.39 Million CAD | 36.0% |
| 2014 | 13.52 Million CAD | 616.7% |
| 2013 | 1.88 Million CAD | 162.66% |
| 2012 | 718.54 Thousand CAD | -35.91% |
| 2011 | 1.12 Million CAD | -19.22% |
| 2010 | 1.38 Million CAD | -19.74% |
| 2009 | 1.72 Million CAD | 6.27% |
| 2008 | 1.62 Million CAD | -3.81% |
| 2007 | 1.69 Million CAD | 280.13% |
| 2006 | 445.06 Thousand CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q3 | 838.67 Million CAD | 2.63% |
| 2023 FY | 838.67 Million CAD | -9.46% |
| 2023 Q1 | 818.37 Million CAD | -24.53% |
| 2023 Q2 | 817.16 Million CAD | -0.15% |
| 2022 Q4 | 1.08 Billion CAD | 17.06% |
| 2022 Q3 | 926.32 Million CAD | -9.52% |
| 2022 Q2 | 1.02 Billion CAD | -12.49% |
| 2022 FY | 926.32 Million CAD | -14.57% |
| 2022 Q1 | 1.16 Billion CAD | 7.89% |
| 2021 Q1 | 2.56 Billion CAD | -1.71% |
| 2021 Q2 | 2.48 Billion CAD | -2.93% |
| 2021 Q3 | 1.57 Billion CAD | -36.82% |
| 2021 Q4 | 1.08 Billion CAD | -30.94% |
| 2021 FY | 1.08 Billion CAD | -58.37% |
| 2020 Q4 | 2.6 Billion CAD | -8.13% |
| 2020 Q3 | 2.83 Billion CAD | 0.18% |
| 2020 Q2 | 2.83 Billion CAD | 2.64% |
| 2020 Q1 | 2.75 Billion CAD | -0.95% |
| 2020 FY | 2.6 Billion CAD | -6.43% |
| 2019 Q2 | 4.67 Billion CAD | -16.67% |
| 2019 Q1 | 5.6 Billion CAD | 1.89% |
| 2019 FY | 2.78 Billion CAD | -49.41% |
| 2019 Q3 | 4.71 Billion CAD | 0.98% |
| 2019 Q4 | 2.78 Billion CAD | -40.99% |
| 2018 Q3 | 5.54 Billion CAD | 13.82% |
| 2018 FY | 5.5 Billion CAD | 188.0% |
| 2018 Q4 | 5.5 Billion CAD | -0.85% |
| 2018 Q2 | 4.87 Billion CAD | -1.6% |
| 2018 Q1 | 4.95 Billion CAD | 159.35% |
| 2017 Q3 | 1.67 Billion CAD | 128.21% |
| 2017 Q4 | 1.91 Billion CAD | 14.32% |
| 2017 FY | 1.91 Billion CAD | 492.14% |
| 2017 Q1 | 347.83 Million CAD | 7.8% |
| 2017 Q2 | 732.39 Million CAD | 110.56% |
| 2016 Q4 | 322.67 Million CAD | 63.74% |
| 2016 Q1 | 56.76 Million CAD | 208.58% |
| 2016 Q2 | 98.21 Million CAD | 73.02% |
| 2016 Q3 | 197.06 Million CAD | 100.64% |
| 2016 FY | 322.67 Million CAD | 1654.02% |
| 2015 FY | 18.39 Million CAD | 36.0% |
| 2015 Q3 | 22.31 Million CAD | 33.17% |
| 2015 Q1 | 13.89 Million CAD | 2.74% |
| 2015 Q2 | 16.76 Million CAD | 20.61% |
| 2015 Q4 | 18.39 Million CAD | -17.58% |
| 2014 Q4 | 13.52 Million CAD | 32.94% |
| 2014 FY | 13.52 Million CAD | 616.7% |
| 2014 Q1 | 5.04 Million CAD | 167.05% |
| 2014 Q3 | 10.17 Million CAD | 4.18% |
| 2014 Q2 | 9.76 Million CAD | 93.77% |
| 2013 Q3 | 582.69 Thousand CAD | -7.18% |
| 2013 FY | 1.88 Million CAD | 162.66% |
| 2013 Q1 | 667.31 Thousand CAD | -7.13% |
| 2013 Q2 | 627.78 Thousand CAD | -5.92% |
| 2013 Q4 | 1.88 Million CAD | 223.9% |
| 2012 Q2 | 880.68 Thousand CAD | -12.19% |
| 2012 Q4 | 718.54 Thousand CAD | -11.37% |
| 2012 FY | 718.54 Thousand CAD | -35.91% |
| 2012 Q1 | 1 Million CAD | -10.55% |
| 2012 Q3 | 810.71 Thousand CAD | -7.94% |
| 2011 Q3 | 1.28 Million CAD | -2.15% |
| 2011 Q1 | 1.34 Million CAD | -2.78% |
| 2011 Q2 | 1.3 Million CAD | -3.06% |
| 2011 Q4 | 1.12 Million CAD | -12.41% |
| 2011 FY | 1.12 Million CAD | -19.22% |
| 2010 Q4 | 1.38 Million CAD | -2.14% |
| 2010 FY | 1.38 Million CAD | -19.74% |
| 2010 Q3 | 1.41 Million CAD | -13.63% |
| 2010 Q2 | 1.64 Million CAD | -2.99% |
| 2010 Q1 | 1.69 Million CAD | -2.12% |
| 2009 Q1 | 1.61 Million CAD | -0.91% |
| 2009 Q4 | 1.72 Million CAD | 4.22% |
| 2009 FY | 1.72 Million CAD | 6.27% |
| 2009 Q3 | 1.65 Million CAD | -5.45% |
| 2009 Q2 | 1.75 Million CAD | 8.84% |
| 2008 FY | 1.62 Million CAD | -3.81% |
| 2008 Q1 | 1.68 Million CAD | -0.21% |
| 2008 Q3 | 1.63 Million CAD | -1.37% |
| 2008 Q4 | 1.62 Million CAD | -0.59% |
| 2008 Q2 | 1.65 Million CAD | -1.69% |
| 2007 FY | 1.69 Million CAD | 280.13% |
| 2007 Q4 | 1.69 Million CAD | -1.21% |
| 2007 Q3 | 1.71 Million CAD | 0.06% |
| 2007 Q2 | 1.71 Million CAD | 286.36% |
| 2007 Q1 | 443 Thousand CAD | 0.0% |
| 2006 FY | 445.06 Thousand CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 904.42 Million USD | 7.27% |
| Aquestive Therapeutics, Inc. | 57.41 Million USD | -1360.645% |
| Collegium Pharmaceutical, Inc. | 1.14 Billion USD | 26.645% |
| Cosmos Health Inc. | 66.29 Million USD | -1165.051% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -6230.784% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -307.526% |
| Cronos Group Inc. | 1.13 Billion USD | 26.059% |
| Incannex Healthcare Limited | 17.04 Million USD | -4819.769% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -1398.996% |
| Lifecore Biomedical, Inc. | 273.7 Million USD | -206.418% |
| Regencell Bioscience Holdings Limited | 8.43 Million USD | -9838.991% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -2966.787% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -2966.787% |
| SCYNEXIS, Inc. | 128.41 Million USD | -553.111% |
| Safety Shot Inc | 12.7 Million USD | -6498.954% |
| Theratechnologies Inc. | 77.76 Million USD | -978.416% |
| Alpha Teknova, Inc. | 128.58 Million USD | -552.222% |
| Universe Pharmaceuticals INC | 53.28 Million USD | -1473.878% |
| Pacira BioSciences, Inc. | 1.57 Billion USD | 46.73% |
| Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | -5531.323% |
| Dynavax Technologies Corporation | 997.09 Million USD | 15.888% |
| Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | -78.035% |
| Radius Health, Inc. | 1.71 Billion USD | 51.125% |
| China SXT Pharmaceuticals, Inc. | 23.12 Million USD | -3526.371% |
| Alvotech | 950.09 Million USD | 11.727% |
| Intra-Cellular Therapies, Inc. | 728.29 Million USD | -15.156% |
| SIGA Technologies, Inc. | 254.83 Million USD | -229.103% |
| Shineco, Inc. | 84.17 Million USD | -896.293% |
| Silver Spike Investment Corp. | 88.57 Million USD | -846.837% |
| Journey Medical Corporation | 76.84 Million USD | -991.326% |
| Petros Pharmaceuticals, Inc. | 33.79 Million USD | -2381.59% |
| Embecta Corp. | 1.21 Billion USD | 30.939% |
| Harrow Health, Inc. | 311.75 Million USD | -169.017% |
| Procaps Group, S.A. | 460.18 Million USD | -82.246% |
| Biofrontera Inc. | 27.93 Million USD | -2902.553% |
| DURECT Corporation | 45.18 Million USD | -1755.923% |
| PainReform Ltd. | 9.93 Million USD | -8345.851% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 40.476% |
| OptiNose, Inc. | 107.72 Million USD | -678.503% |
| RedHill Biopharma Ltd. | 23.04 Million USD | -3538.947% |
| Organogenesis Holdings Inc. | 460.02 Million USD | -82.31% |
| Cumberland Pharmaceuticals Inc. | 81.77 Million USD | -925.573% |
| ProPhase Labs, Inc. | 91.92 Million USD | -812.325% |
| Phibro Animal Health Corporation | 982.18 Million USD | 14.611% |
| Procaps Group S.A. | 460.18 Million USD | -82.246% |
| TherapeuticsMD, Inc. | 43.3 Million USD | -1836.487% |
| Viatris Inc. | 47.68 Billion USD | 98.241% |
| Rockwell Medical, Inc. | 52.17 Million USD | -1507.485% |
| Aytu BioPharma, Inc. | 118.09 Million USD | -610.168% |
| Tilray Brands, Inc. | 4.33 Billion USD | 80.655% |
| PetIQ, Inc. | 868.22 Million USD | 3.404% |
| Talphera, Inc. | 20.39 Million USD | -4012.15% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 74.206% |
| Alimera Sciences, Inc. | 153.52 Million USD | -446.281% |
| Assertio Holdings, Inc. | 286.41 Million USD | -192.813% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -13991.233% |
| Avadel Pharmaceuticals plc | 261.12 Million USD | -221.176% |
| Hempacco Co., Inc. | 18.04 Million USD | -4548.17% |
| Alvotech | 950.09 Million USD | 11.727% |
| Lantheus Holdings, Inc. | 1.65 Billion USD | 49.207% |
| Kamada Ltd. | 351.96 Million USD | -138.28% |
| Currenc Group, Inc. | 141.49 Million USD | -492.742% |
| Indivior PLC | 1.95 Billion USD | 57.018% |
| Evoke Pharma, Inc. | 7.06 Million USD | -11764.859% |
| Flora Growth Corp. | 23.62 Million USD | -3449.788% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -6230.784% |
| Evolus, Inc. | 188.99 Million USD | -343.747% |
| HUTCHMED (China) Limited | 1.27 Billion USD | 34.467% |
| Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 44.566% |
| Akanda Corp. | 8.83 Million USD | -9387.259% |